Teva and Allergan have put aside their differences—and the result is an influx of cash that Teva badly needs.
Wednesday, the former deal partners inked an agreement to settle a dispute over the amount of working capital that changed hands when Teva took over Allergan’s generics unit last year. Allergan will fork over $700 million, and Teva says it’ll use that money to repay some of the debt it incurred with that disastrous $40.5 billion buy.
Back in November, the embattled Israeli drugmaker noted that the final cash consideration from its $40.5 billion buyout of Allergan’s generics unit was in need of tweaking. As a starting point before heading into arbitration, Teva suggested Allergan hand over $1.4 billion. Meanwhile, the Israeli company cautioned investors in a financial filing that the amount it eventually received “could be significantly lower than the amount submitted.”
That turned out to be the case in the final settlement. But while Teva will only receive half the sum it desired, it can definitely put the $700 million to use. Since the Allergan pickup—which proved to be devastating, thanks to buyer consolidation that’s forced generics prices down—Teva has struggled hard, and the mountain of debt it incurred with the buyout has made things even more complicated. In November, easing the debt burden became extra difficult as credit rating agency Fitch cut Teva’s rating to junk.
New CEO Kåre Schultz, though, has a plan he’s confident can get the company back on track, if a controversial one. In December, Teva announced 14,000 job cuts it said would help it save $3 billion per year.
Allergan, meanwhile, isn’t exactly in peak shape, either. Last month, to prepare for potential generic competition to blockbuster Restasis, it slashed 1,400 jobs of its own. The move, execs said, would help the company save between $300 million and $400 million off the operating cost total it rung up in 2017—or, in other words, about half the bill it now owes Teva.
By Carly Helfand
Source: Fierce Pharma
Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.
Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.
Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.